Tuesday, April 2, 2019

Please note that PDF versions of PowerPoint files presented during TAT 11 are included only where permission to do so was provided by the speaker. Click on the name of the presentation to download the pdf file.

Opening Session

 

Pretargeted Ac-225 Radiommunotherapy Strategies

Dr. Jason S. Lewis, Vice Chair for Research, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center

 

Contribution of Targeted and Off-target Effects during Radionuclide Therapy using High-LET Particles

Dr. Jean-Pierre Pouget, Head, Radiobiology and Targeted Radiotherapy Team, Institut de Recherche en Cancérologie de Montpellier

 

Ac-225 Preclinical

 

Highly Effective Treatment of CD38 Positive Experimental Lymphoma with Actinium-225-Daratumumab

Dr. Wojciech Dawicki, University of Saskatchewan

 

Ac-225-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts

Mr. Robin Merkx, Radboudumc, Nijmegen

 

Radiometals Preclinical

 

IGFR-1 Targeted Alpha Therapeutic FPI-1434 Causes DNA Double-stranded Breaks and Induces Regression in Preclinical Models of Human Cancer

Dr. Eric Burak, Fusion Pharmaceuticals

Combining Bismuth-213 with Nanobodies: Finding the Perfect Match for Targeted Alpha Therapy

Ms. Yana Dekempeneer, Studiecentrum voor Kernenergie (SCK-CEN)

 

212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Dr. Amal Saidi, Orano Med

Other Radionuclides

 

The Use of Albumin Binders as a Strategy to Optimize Tumour Delivery of Therapeutic Radioisotopes

Dr. Kuo-Shyan Lin, Senior Scientist, BC Cancer, Department of Molecular Oncology, and Associate Professor, the University of British Columbia, Department of Radiology

 

Radiohalogenated Neopentyl Derivatives: A Novel Scaffold for Radioiodinated and Astatinated Compounds of High Stability to In Vivo Dehalogenation

Dr. Hiroyuki Suzuki, Chiba University, Graduate School of Pharmaceutical Sciences

 

Tuning of the Radium Biodistribution by Dietary Supplements in a CD1 Mice Model

Dr. Ján Kozempel, Czech Technical University in Prague

 

Preclinical in Vitro Nanocarriers/Safety, Regulation

 

Nanoparticles for the Treatment of Metastatic Non Small Cell Lung Cancer with Ac-225

Dr. Charles Maitz, University of Missouri, College of Veterinary Medicine and Surgery

 

Consideration toward Safety Guidance for Targeted Alpha Therapy in Japan

Prof. Tsuneo Yano, Osaka University, RCNP

 

The Role of the IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters

Dr. Amirreza Jalilian, International Atomic Energy

 

Wednesday, April 3, 2019

Opening Session

 

Has the Dream Come True? A Retrospective Look at the Development of Alpha Therapy and its Promise for the Future

Dr. Thomas Ruth, Emeritus Senior Research Scientist, TRIUMF

 

Perspectives on the Production and Radiopharmaceutical Chemistry of Ac-225 and other Alpha Emitters

Dr. Paul Schaffer, Associate Laboratory Director, Life Sciences, TRIUMF

Innovation, Impact and Strategic Importance of Alpha Emitting Radionuclides

Dr. Saed Mirzadeh, Corporate Fellow, Oak Ridge National Lab

Radiochemistry

 

New Bifunctional Chelators for Ac-225 and 227Th Radioimmunotherapy

Ms. Lily Li, University of British Columbia

 

Various Chromatographic Schemes for Separation of 213Bi from Ac-225

Dr. Aleksandr Vasiliev, Institute for Nuclear Research of Russian Academy of Sciences

 

Evaluation of Inorganic ion Exchange Materials for Purification of Ac-225 from Thorium and Radium Radioisotopes

Mr. Jonathan Fitzsimmons, Brookhaven National Lab

 

Evaluation of Specific activity and Stable Impurities in Ac-225 Derived from ISAC and 229Th Decay

Ms. Jenasee Mynerich, TRIUMF, McMaster University

 

Radiochemistry cont’d

 

Astatine-211: The Chemistry Infrastructure

Dr. Sture Lindegren, Gothenburg University, Department of Radiation Physics

 

Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211

Dr. Yawen Li, University of Washington-Seattle

 

Advances in the Radiolabeling of Antibodies with Astatine-211: Toward Simplified Procedures and Improved Radiochemical Yields

Dr. Jean-François Gestin, Institut national de la santé et de la recherche médicale (INSERM)

 

212Pb Production and Investigation of a Preparation Based on this Radionuclide for Therapy of Neuroendocrine Tumors

Mr. Konstantin Kokov, National Research Center Kurchatov Institute

 

Nuclide Production

 

U.S. DOE Tri-Lab Research and Production Effort to Provide Accelerator-Produced Ac-225 for Radiotherapy: 2019 Update

Dr. Kevin John, Los Alamos National Laboratory

 

Selective Separation of Radium and Actinium from Bulk Thorium Target Material

Mr. Daniel McAlister, Eichrom Technologies, LLC

 

Nuclide Production, cont’d

 

High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac

Dr. Terry Grimm, Niowave, Inc.

 

NorthStar Program for Production of Ac-225

Dr. James Harvey, NorthStar Medical Technologies, LLC

 

Dosimetry

 

Optimization of Dosimetry in Alphatherapy: Microlocalisation of 223Ra in Mouse Models of Metastasis from Prostate Cancer and Renal Cell Carcinoma

Dr. Nadia Benabdallah, Institute for Radiological Protection and Nuclear Safety

 

Pharmacokinetic Variability of In Vivo Generated 213Bi and Vector Labeled Ac-225 in Murine Cancer Models

Dr. Anders Josefsson, Johns Hopkins University School of Medicine

 

Small Scale Modeling and Dosimetry for the Salivary Gland: Application to 177Lu- and Ac-225-PSMA Therapy

Dr. Robert Hobbs, Johns Hopkins University

 

Development and Validation of Methods for Quantitative In Vivo SPECT of Pb-212

Mr. Eric Frey, Radiopharmaceuticals Imaging and Dosimetry

Thursday, April 4, 2019

Session I. Alpha as a New Tool in the Clinical Armamentarium – Basic Concepts

 

The Clinical Case for Incorporating Dosimetry in Alpha-Emitter Therapy

Dr. George Sgouros, Professor of Radiology & Radiological Science, Johns Hopkins University, School of Medicine

Tarteget Radioimmunotherapy and Theranostics

Dr. Neeta Pandit-Taskar, Attending, Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, NY

 

Session II. Ra-223 Therapy as an Approved Modality for Treatment of Bony Metastases:
From ALSYMPCA to Clinical Practice at The Ottawa Hospital

 

A Radiation Safety Perspective

Mr. Jon Aro, Radiation Safety Officer, The Ottawa Hospital

 

Session III. Regulatory Aspects of Alpha Therapy

 

Panel Discussion – A Canadian Perspective

Dr. Corinne Bensimon, Senior Reviewer, CMC, Radiopharmaceuticals and Gene Therapies Unit CERB, Health Canada

Mr. Patrick Ruddock, Manager, Regulatory Affairs, Centre for Probe Development and Commercialization

Mr. Paul Gustafson, Senior Corporate Regulatory Compliance and Enforcement Advisor, Regulatory Operations and Enforcement Branch, Health Canada

 

Session IV. Emerging Vistas in Alpha Therapy

 

Targeted Alpha-Particle Therapy for Hematologic Malignancies

Dr. Joseph G. Jurcic, Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology

 

Future Vistas in Alpha Therapy of Infectious Diseases

Dr. Ekaterina Dadachova, Sylvia Fedoruk Centre for Nuclear Innovation Chair in Radiopharmacy and Professor, University of Saskatchewan

 

Session V. Clinical Abstract Presentations

 

Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy

Dr. Lior Arazi, Nuclear Engineering Unit, Faculty of Engineering Sciences, Ben-Gurion University

 

Improved Tumor Control and Absence of Late Neurotoxicity using Alpha (213Bi) as Compared to Beta (90Y) Labelled-DOTA-Substance P for the Treatment of Low Grade Gliomas

Prof. Adrian Merlo, University of Basel

 

Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)

Dr. Ebrahim S. Delpassand, RadioMedix Inc.

 

Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed

Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations

Dr. Per Albertsson, Department of Oncology, Sahlgrenska University Hospital

 

Session VI. Conference Summation and Overview

 

Where Do We See Alpha Emitters in Clinical Practice. A Radiation Oncology Perspective

Dr. Joe O’Sullivan, Prostate Cancer Oncologist, Norther Ireland Cancer Centre & Professor of Radiation Oncology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast

 

Alpha Therapeutics from a Prostate Oncologic Standpoint

Dr. Michael Morris, Section Head, Prostate Cancer, Memorial Sloan Kettering Cancer Center